• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在实体器官移植受者中的猴痘临床特征、治疗和转归:一项多中心病例系列研究和文献复习。

Clinical features, treatment, and outcomes of mpox in solid organ transplant recipients: A multicenter case series and literature review.

机构信息

Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Department of Infectious Diseases, Cleveland Clinic, Cleveland, Ohio, USA.

出版信息

Am J Transplant. 2023 Dec;23(12):1972-1979. doi: 10.1016/j.ajt.2023.07.016. Epub 2023 Jul 27.

DOI:10.1016/j.ajt.2023.07.016
PMID:37516243
Abstract

In 2022, the largest global outbreak of mpox to date emerged. In the immunocompetent host, mpox generally presents as a self-limiting illness. However, immunosuppression, such as that seen with advanced HIV, has been associated with significant morbidity and mortality related to mpox infection. To evaluate the impact of immunosuppression related to solid organ transplantation on clinical features and outcomes of mpox we established a multicenter case registry. Eleven cases from 7 participating centers in the USA were submitted. All cases occurred in males. The majority were kidney transplant recipients (91%, n = 10). Median duration of symptoms at presentation was 6 days (range, 3-14 days). Rates of hospitalization were high (73%, n = 8) with a median length of stay of 4.5 days (range, 1-10 days). Mpox in solid organ transplant recipients was associated with a high burden of skin lesions and systemic symptoms. Fever, fatigue, pharyngitis, and proctitis were commonly reported. Other clinical features included headache, myalgia, epididymo-orchitis, urinary retention, hematemesis, pneumonitis, and circulatory shock. All patients received treatment with tecovirimat. There was 1 mpox-related death in the cohort. Infection was reported to have resolved at 30-day follow-up in all other cases.

摘要

2022 年,出现了迄今为止最大的猴痘全球疫情。在免疫功能正常的宿主中,猴痘通常表现为自限性疾病。然而,免疫抑制,如晚期 HIV 所导致的免疫抑制,与猴痘感染相关的发病率和死亡率显著增加有关。为了评估与实体器官移植相关的免疫抑制对猴痘临床特征和结局的影响,我们建立了一个多中心病例登记处。来自美国 7 个参与中心的 11 例病例被提交。所有病例均发生于男性。大多数为肾移植受者(91%,n=10)。发病时症状的中位持续时间为 6 天(范围,3-14 天)。住院率很高(73%,n=8),中位住院时间为 4.5 天(范围,1-10 天)。实体器官移植受者中的猴痘与皮肤损伤和全身症状负担高有关。发热、疲劳、咽炎和直肠炎是常见的报告症状。其他临床特征包括头痛、肌痛、附睾炎或睾丸炎、尿潴留、呕血、肺炎和循环性休克。所有患者均接受特考韦瑞治疗。该队列中有 1 例猴痘相关死亡。在所有其他病例中,报告在 30 天随访时感染已得到解决。

相似文献

1
Clinical features, treatment, and outcomes of mpox in solid organ transplant recipients: A multicenter case series and literature review.在实体器官移植受者中的猴痘临床特征、治疗和转归:一项多中心病例系列研究和文献复习。
Am J Transplant. 2023 Dec;23(12):1972-1979. doi: 10.1016/j.ajt.2023.07.016. Epub 2023 Jul 27.
2
Monkeypox in a Kidney Transplant Recipient: Case Report and Literature Review.肾移植受者中的猴痘病例报告及文献复习。
Exp Clin Transplant. 2023 Nov;21(11):913-916. doi: 10.6002/ect.2023.0222.
3
The impact of immunosuppression on the mortality and hospitalization of Monkeypox: a systematic review and meta-analysis of the 2022 outbreak.免疫抑制对猴痘病死率和住院率的影响:2022 年猴痘疫情的系统评价和荟萃分析。
Virol J. 2024 Jun 5;21(1):130. doi: 10.1186/s12985-024-02392-0.
4
The successful treatment of mpox with brincidofovir in renal transplant recipients-a report of 2 cases.肾移植受者用溴昔洛韦成功治疗猴痘——2 例报告。
Int J Infect Dis. 2024 Jun;143:107015. doi: 10.1016/j.ijid.2024.107015. Epub 2024 Mar 21.
5
Mpox severity and associated hospitalizations among people with HIV and related immunosuppression in Brazil.巴西艾滋病毒感染者和相关免疫抑制人群中猴痘的严重程度和相关住院情况。
AIDS. 2024 Jan 1;38(1):105-113. doi: 10.1097/QAD.0000000000003748. Epub 2023 Oct 12.
6
Clinical features and management of individuals admitted to hospital with monkeypox and associated complications across the UK: a retrospective cohort study.在英国,因感染猴痘及相关并发症住院的个体的临床特征和管理:一项回顾性队列研究。
Lancet Infect Dis. 2023 May;23(5):589-597. doi: 10.1016/S1473-3099(22)00806-4. Epub 2022 Dec 22.
7
First case of rapidly fatal mpox from secondary (household) transmission in a kidney transplant recipient.首例肾移植受者继发(家庭)传播的快速致命猴痘病例。
Am J Transplant. 2023 Dec;23(12):1995-1999. doi: 10.1016/j.ajt.2023.07.017. Epub 2023 Jul 28.
8
COVID-19 in solid organ transplant recipients: Initial report from the US epicenter.COVID-19 于实体器官移植受者:来自美国震中地区的初步报告。
Am J Transplant. 2020 Jul;20(7):1800-1808. doi: 10.1111/ajt.15941. Epub 2020 May 10.
9
Case Report: Mpox - Not Just a Rash.病例报告:猴痘——不仅仅是皮疹。
Am J Trop Med Hyg. 2023 Jan 30;108(3):592-594. doi: 10.4269/ajtmh.22-0626. Print 2023 Mar 1.
10
Comparative evaluation of the clinical presentation and epidemiology of the 2022 and previous Mpox outbreaks: a rapid review and meta-analysis.2022 年与既往猴痘疫情的临床特征和流行病学比较评估:快速综述和荟萃分析。
Infect Dis (Lond). 2023 Jul;55(7):490-508. doi: 10.1080/23744235.2023.2214609. Epub 2023 May 18.

引用本文的文献

1
A Severe Form of Mpox Infection and the Current Epidemiological Status in Romania.罗马尼亚的一种严重形式的猴痘感染及当前流行病学状况。
Microorganisms. 2025 Aug 3;13(8):1814. doi: 10.3390/microorganisms13081814.
2
Isolation and Characterization of E8 Monoclonal Antibodies from Donors Vaccinated with Recombinant Vaccinia Vaccine with Efficient Neutralization of Authentic Monkeypox Virus.从接种重组痘苗病毒疫苗的供体中分离并鉴定出E8单克隆抗体,该抗体对正宗猴痘病毒具有高效中和作用。
Vaccines (Basel). 2025 Apr 27;13(5):471. doi: 10.3390/vaccines13050471.
3
Monkeypox infection in kidney transplant recipients.
肾移植受者中的猴痘感染。
Clin Kidney J. 2025 Feb 12;18(3):sfaf048. doi: 10.1093/ckj/sfaf048. eCollection 2025 Mar.
4
Urogenital Manifestations in Mpox (Monkeypox) Infection: A Comprehensive Review of Epidemiology, Pathogenesis, and Therapeutic Approaches.猴痘感染中的泌尿生殖系统表现:流行病学、发病机制及治疗方法的综合综述
Infect Drug Resist. 2025 Jan 10;18:209-226. doi: 10.2147/IDR.S504280. eCollection 2025.
5
Monkeypox: a re-emergent virus with global health implications - a comprehensive review.猴痘:一种对全球健康有影响的再现病毒——全面综述
Trop Dis Travel Med Vaccines. 2025 Jan 15;11(1):2. doi: 10.1186/s40794-024-00237-w.
6
Mpox treatment evolution: past milestones, present advances, and future directions.猴痘治疗的演变:过去的里程碑、当前的进展及未来的方向。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Feb;398(2):1057-1080. doi: 10.1007/s00210-024-03385-0. Epub 2024 Sep 3.
7
The impact of immunosuppression on the mortality and hospitalization of Monkeypox: a systematic review and meta-analysis of the 2022 outbreak.免疫抑制对猴痘病死率和住院率的影响:2022 年猴痘疫情的系统评价和荟萃分析。
Virol J. 2024 Jun 5;21(1):130. doi: 10.1186/s12985-024-02392-0.
8
Antivirals against Monkeypox (Mpox) in Humans: An Updated Narrative Review.用于人类抗猴痘的抗病毒药物:最新叙述性综述
Life (Basel). 2023 Sep 26;13(10):1969. doi: 10.3390/life13101969.